A pilot study of prospective observational cohort study to assess the profile of OAD dual combination therapy in patients with T2DM in real practice
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0000437
- Lead Sponsor
- Chonnam National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 288
Male or female patients = 18 years
- Patients diagnosed with type 2 DM, on metformin monotherapy, who will be prescribed a new OAD or an OAD fixed-dose combination as dual combination therapy according to local label/prescribing requirements.
- 7=HbA1c=11
- Patients give informed consent to have their data collected and agree to follow prescribing requirements
- Patients who require three or more OAD or insulin at time of study entry.
- Patients who are switched from
one OAD or class to another at time of study entry.
- History of hypersensitivity to any of the study drug.
- Patients who are attending other study and use of any drug.
- Patients who are taking SUs other than glimepiride at study entry
-Patients for whom the investigator would consider another SU than glimepiride during the course of the trial
- Patients treated with glinides at study entry
-patients for which a treatment with glinides would be considered during the course of the study
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dual drug withdrawal(failure) means, patients who need three OAD or more or insulin or HbA1c >7.5% twice ( 2 consecutive failure)
- Secondary Outcome Measures
Name Time Method